A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in Adult Participants With Relapsed/Refractory CD19-positive B-cell Malignant Hematological Tumors

This study is a prospective single-arm open-label clinical trial, including dose escalation and expansion phase, aims to evaluate the safety, efficacy, and cellular pharmacokinetics of GT719 Injection in relapsed/refractory CD19 positive adult B-cell non Hodgkin lymphoma (B-NHL) and B-acute lymphoblastic leukemia (B-ALL) patients. A total of 34 subjects will be enrolled in this study.

Trial Details

NCT ID
NCT07131254
Phase
EARLY_PHASE1
Sponsor
Grit Biotechnology
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • GT719 Injection
Locations (sample)
  • Ganzhou, Jiangxi, China|25.84664,114.9326

Key Eligibility Criteria

  • 1\. Voluntarily enrolled in the study, signed an informed consent form, willing and able to comply with the study protocol.
  • 2\. Aged 18 to 75 years (inclusive), regardless of gender.
  • 3\. Participants with refractory or relapsed acute B-cell lymphoblastic leukemia or B-cell lymphoma diagnosed according to the WHO 2016 classificat…
  • 4\. CD19 positivity confirmed by flow cytometry and/or histopathology.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →